Nuveen’s 2seventy bio TSVT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-93,115
| Closed | -$466K | – | 3314 |
|
|
2025
Q2 | $466K | Sell |
93,115
-10,533
| -10% | -$52.4K | ﹤0.01% | 2908 |
|
|
2025
Q1 | $512K | Hold |
103,648
| – | – | ﹤0.01% | 2899 |
|
|
2024
Q4 | $305K | Hold |
103,648
| – | – | ﹤0.01% | 3123 |
|
|
2024
Q3 | $489K | Sell |
103,648
-6,681
| -6% | -$30.1K | ﹤0.01% | 3027 |
|
|
2024
Q2 | $425K | Buy |
110,329
+13,150
| +14% | +$59.3K | ﹤0.01% | 3045 |
|
|
2024
Q1 | $520K | Hold |
97,179
| – | – | ﹤0.01% | 2963 |
|
|
2023
Q4 | $415K | Buy |
97,179
+542
| +0.6% | +$1.67K | ﹤0.01% | 3067 |
|
|
2023
Q3 | $379K | Sell |
96,637
-1,275
| -1% | -$8.36K | ﹤0.01% | 2921 |
|
|
2023
Q2 | $991K | Buy |
97,912
+23,231
| +31% | +$246K | ﹤0.01% | 2665 |
|
|
2023
Q1 | $762K | Sell |
74,681
-18,031
| -19% | -$206K | ﹤0.01% | 2699 |
|
|
2022
Q4 | $869K | Sell |
92,712
-17,709
| -16% | -$250K | ﹤0.01% | 2739 |
|
|
2022
Q3 | $1.61M | Sell |
110,421
-1,968
| -2% | -$29.2K | ﹤0.01% | 2516 |
|
|
2022
Q2 | $1.48M | Buy |
112,389
+27,003
| +32% | +$368K | ﹤0.01% | 2600 |
|
|
2022
Q1 | $1.39M | Buy |
85,386
+895
| +1% | +$15.2K | ﹤0.01% | 2677 |
|
|
2021
Q4 | $2.29M | Buy |
+84,491
| New | +$2.64M | ﹤0.01% | 2508 |
|
Nuveen's TSVT Position: Q3 2025 in Review
Nuveen sold out of 2seventy bio (TSVT) in Q3 2025, closing a stake of 93,115 shares — an estimated $466K sold.
Nuveen first reported a position in TSVT in Q4 2021 and held it in 15 quarters. The position peaked at $2.29M in Q4 2021. 0 funds tracked by Wall St. Rank hold TSVT as of Q3 2025.
- Nuveen reported no remaining 2seventy bio position as of Q3 2025 after selling out during the quarter.
- Nuveen sold 93,115 2seventy bio shares in Q3 2025, an estimated $466K.
- Nuveen first reported a position in 2seventy bio in Q4 2021 and held it in 15 quarters.
- Nuveen's 2seventy bio position peaked at $2.29M in Q4 2021.
- 0 funds tracked by Wall St. Rank held 2seventy bio as of Q3 2025.
Based on Nuveen's 13F filing for Q3 2025, filed 12 Nov 2025.